menu
    • menu
    [{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"Pyros Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Vigabatrin","moa":"||GABA transaminase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Bora Pharmaceuticals \/ Bora Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Bora Pharmaceuticals \/ Bora Pharmaceuticals"},{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"Upsher-Smith Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Amantadine Hydrochloride","moa":"||MMP-2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bora Pharmaceuticals \/ Bora Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Bora Pharmaceuticals \/ Bora Pharmaceuticals"},{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"Upsher-Smith Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Amantadine Hydrochloride","moa":"||MMP-2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bora Pharmaceuticals \/ Bora Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Bora Pharmaceuticals \/ Bora Pharmaceuticals"},{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"TaiRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Foslinanib","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Bora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bora Pharmaceuticals \/ TaiRx","highestDevelopmentStatusID":"8","companyTruncated":"Bora Pharmaceuticals \/ TaiRx"},{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"Celltrion","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"CT-G20","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Bora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bora Pharmaceuticals \/ Celltrion","highestDevelopmentStatusID":"6","companyTruncated":"Bora Pharmaceuticals \/ Celltrion"},{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"Kyowa Pharmaceutical Industry","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Bora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bora Pharmaceuticals \/ Bora Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Bora Pharmaceuticals \/ Bora Pharmaceuticals"},{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"Evofem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Bora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Bora Pharmaceuticals \/ Bora Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Bora Pharmaceuticals \/ Bora Pharmaceuticals"},{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"DotBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody","year":"2025","type":"Collaboration","leadProduct":"DB007","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Bora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bora Pharmaceuticals \/ DotBio","highestDevelopmentStatusID":"4","companyTruncated":"Bora Pharmaceuticals \/ DotBio"}]

    Find Clinical Drug Pipeline Developments & Deals by Bora Pharmaceuticals

    Menu

    Bora Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bora Pharmaceuticals

                            Taiwan arrow
                            EPSC
                            Not Confirmed

                            Bora Pharmaceuticals

                            Taiwan arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DB007,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : DotBio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Bora Biologics, DotBio Enter Strategic CMC Development Collaboration

                            Details : The collaboration aims to advance the development of DotBio’s Tri-Specific Antibody DB007 for the treatment of Cancer.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            January 09, 2025

                            Lead Product(s) : DB007,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : DotBio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bora Pharmaceuticals

                            Taiwan arrow
                            EPSC
                            Not Confirmed

                            Bora Pharmaceuticals

                            Taiwan arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vigabatrin,Inapplicable

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : Pyros Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Bora Expands Rare Disease Portfolio with Pyros Pharma Acquisition

                            Details : Through the acquisition of US-based Pyros, Bora will expand his pipelines by adding some candidates such as Vigafyde (vigabatrin), which is indicated for the treatment of infantile spasms.

                            Product Name : Vigafyde

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 25, 2024

                            Lead Product(s) : Vigabatrin,Inapplicable

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : Pyros Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bora Pharmaceuticals

                            Taiwan arrow
                            EPSC
                            Not Confirmed

                            Bora Pharmaceuticals

                            Taiwan arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amantadine Hydrochloride,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Recipient : Upsher-Smith Laboratories

                            Deal Size : $210.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            CDMO Bora Pharmaceuticals Buys Generics Manufacturer Upsher-Smith for $210M

                            Details : Bora acquires Upsher-Smith’s product portfolio, including Amantadine hydrochloride for treating influenza A virus infections.

                            Product Name : Amantadine HCl-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 18, 2024

                            Lead Product(s) : Amantadine Hydrochloride,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Upsher-Smith Laboratories

                            Deal Size : $210.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Bora Pharmaceuticals

                            Taiwan arrow
                            EPSC
                            Not Confirmed

                            Bora Pharmaceuticals

                            Taiwan arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amantadine Hydrochloride,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Recipient : Upsher-Smith Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Bora Pharmaceuticals Completes Acquisition of Upsher-Smith

                            Details : Through the acquisition, Bora will commercialize Amantadine HCl-Generic, which is an NMDA receptor inhibitor. It is indicated for the treatment of influenza A infections and Parkinsonism.

                            Product Name : Amantadine HCl-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 04, 2024

                            Lead Product(s) : Amantadine Hydrochloride,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Upsher-Smith Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Bora Pharmaceuticals

                            Taiwan arrow
                            EPSC
                            Not Confirmed

                            Bora Pharmaceuticals

                            Taiwan arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CT-G20,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Celltrion

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Bora and Celltrion Join Forces To Distribute Oral Drugs Across APAC

                            Details : Under the partnership, Bora will manufacture and commercialize a range of oral dosage form drugs (OSD), including CT-G20, a hypertrophic cardiomyopathy treatment candidate, across the APAC region.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 04, 2023

                            Lead Product(s) : CT-G20,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Celltrion

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Bora Pharmaceuticals

                            Taiwan arrow
                            EPSC
                            Not Confirmed

                            Bora Pharmaceuticals

                            Taiwan arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : L-Lactic Acid,Citric Acid,Potassium Bitartrate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Recipient : Evofem Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Evofem Biosciences to Decrease Cost of Goods 45 Percent Through New Partnership with Bora Pharmaceutical Servi...

                            Details : Initially, Bora will manufacture Phexxi for nations currently considering formal regulatory approval of Phexxi (L-lactic Acid), for the prevention of pregnancy, including Mexico and Nigeria.

                            Product Name : Phexxi

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 05, 2022

                            Lead Product(s) : L-Lactic Acid,Citric Acid,Potassium Bitartrate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Recipient : Evofem Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Bora Pharmaceuticals

                            Taiwan arrow
                            EPSC
                            Not Confirmed

                            Bora Pharmaceuticals

                            Taiwan arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Foslinanib,Sorafenib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : TaiRx

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Bora Pharmaceuticals Partners with TaiRx

                            Details : CVM-1118 (foslinanib) is a new small molecule chemical entity and a potential anti-cancer agent in numerous human cancer cell lines with strong anti-cancer activity, high safety margin, and multiple mechanisms of actions in targeting cancer-specific fact...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 27, 2022

                            Lead Product(s) : Foslinanib,Sorafenib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : TaiRx

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Bora Pharmaceuticals

                            Taiwan arrow
                            EPSC
                            Not Confirmed

                            Bora Pharmaceuticals

                            Taiwan arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Technology

                            Study Phase : Undisclosed

                            Recipient : Kyowa Pharmaceutical Industry

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            KYOWA Pharmaceutical Industry Co. Ltd. Partners with Bora Pharmaceuticals to Manufacture Generic Product for F...

                            Details : Upon PMDA’s approval, Bora will be the commercial manufacturing site for the generic product production. Bora Pharmaceuticals’ sites already have an excellent track record with many regulatory agencies around the world.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 08, 2021

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Technology

                            Highest Development Status : Undisclosed

                            Recipient : Kyowa Pharmaceutical Industry

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth